1. Detection of MET amplification by droplet digital PCR in peripheral blood samples of non-small cell lung cancer

   • Ying Fan
   • Rui Sun
   • Jie Ma

   Original Article – Clinical Oncology 18 May 2022 Pages: 1667 - 1677

   

2. The joint detection of CEA and ctDNA in cerebrospinal fluid: an auxiliary tool for the diagnosis of leptomeningeal metastases in cancer

   • Yong Wang
   • Ningning Luo
   • Shuanghu Yuan

   Original Article – Clinical Oncology 18 May 2022 Pages: 1679 - 1690

   

3. Machine learning for optimized individual survival prediction in resectable upper gastrointestinal cancer

   • Jin-On Jung
   • Nerma Crnovrsanin
   • Thomas Schmidt

   Original Article – Clinical Oncology Open access 26 May 2022 Pages: 1691 - 1702

   

4. Quality assurance and improvement in oncology using guideline-derived quality indicators – results of gynaecological cancer centres certified by the German cancer society (DKG)

   • E. Griesshammer
   • S. Wesselmann
   • J. Sehouli

   Original Article – Clinical Oncology Open access 03 June 2022 Pages: 1703 - 1715

   

5. Pre-operative radiotherapy is associated with superior local relapse-free survival in advanced synovial sarcoma

   • Monika Scheer
   • Erika Hallmen
   • Cooperative Weichteilsarkom Studiengruppe [CWS]

   Original Article – Clinical Oncology Open access 10 June 2022 Pages: 1717 - 1731

   

6. Awareness and use of psychosocial care among cancer patients and their relatives—a comparison of people with and without a migration background in Germany

   • Susanne Singer
   • Nicola Riccetti
   • Kerstin Hermes-Moll

   Original Article – Clinical Oncology Open access 11 June 2022 Pages: 1733 - 1745

   

7. Correlation of PD-L1 expression on tumour cells between diagnostic biopsies and surgical specimens of lung cancer in real life with respect to biopsy techniques and neoadjuvant treatment

   • D. Gompelmann
   • K. Sinn
   • M. A. Hoda

   Original Article – Clinical Oncology Open access 16 June 2022 Pages: 1747 - 1754

   

8. Real-world progression-free survival (rwPFS) and the impact of PD-L1 and smoking in driver-mutated non-small cell lung cancer (NSCLC) treated with immunotherapy

   • J. Nicholas Bodor
   • Jessica R. Bauman
   • Joseph Treat

   Original Article – Clinical Oncology 16 June 2022 Pages: 1755 - 1763

   

9. Continued adjuvant FOLFIRINOX for BRPC or LAPC after neoadjuvant FOLFIRINOX

   • Jaewoo Park
   • Hae Young Kim
   • Jaihwan Kim

   Original Article – Clinical Oncology 20 June 2022 Pages: 1765 - 1775

   

10. Is adjacent lobe invasion an T category upgrade factor for resected non-small cell lung cancer ≤ 5 cm?

    • Jing-Sheng Cai
    • Qian-Yi Lin
    • Xiao-Meng Dou

    Original Article – Clinical Oncology 21 June 2022 Pages: 1777 - 1784

    

11. Homeopathy effects in patients during oncological treatment: a systematic review

    • Anna Wagenknecht
    • Jennifer Dörfler
    • Jutta Huebner

    Original Article – Clinical Oncology Open access 22 June 2022 Pages: 1785 - 1810

    

12. Prevalence of lung tumors in patients with esophageal squamous cell carcinoma and vice versa: a systematic review and meta-analysis

    • Laurelle van Tilburg
    • Steffi E. M. van de Ven
    • Arjun D. Koch

    Original Article – Clinical Oncology Open access 23 June 2022 Pages: 1811 - 1823

    

13. Programmed cell death 1 pathway inhibitors improve the overall survival of small cell lung cancer patients with brain metastases

    • JiaYu Chang
    • XuQuan Jing
    • Yan Zhang

    Original Article – Clinical Oncology Open access 23 June 2022 Pages: 1825 - 1833

    

14. Bone-specific response according to MDA criteria predicts immunotherapy efficacy among advanced non-small cell lung cancer (NSCLC) patients

    • Andrea De Giglio
    • Chiara Deiana
    • Alessandro Di Federico

    Original Article – Clinical Oncology Open access 24 June 2022 Pages: 1835 - 1847

    

15. Efficacy and tolerability of fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in unselected patients with advanced gastric and gastroesophageal cancer: does age really matter?

    • Christian Möhring
    • Aliki Timotheou
    • Maria A. Gonzalez-Carmona

    Original Article – Clinical Oncology 28 June 2022 Pages: 1849 - 1862

    

16. Cannabinoid consumption among cancer patients receiving systemic anti-cancer treatment in the Netherlands

    • Yrina Oelen
    • Sven Revenberg
    • Liselot Valkenburg-van Iersel

    Original Article – Clinical Oncology Open access 02 July 2022 Pages: 1863 - 1872

    

17. Sorafenib plus drug-eluting bead transarterial chemoembolization for early intrahepatic stage-progressed advanced hepatocellular carcinoma refractory to conventional transarterial chemoembolization

    • Wenzhe Fan
    • Bowen Zhu
    • Jiaping Li

    Original Article – Clinical Oncology 05 July 2022 Pages: 1873 - 1882

    

18. Comparative analysis of rituximab or obinutuzumab combined with CHOP in first-line treatment of follicular lymphoma

    • Gwladys Claustre
    • Coralie Boulanger
    • Véronique Graff

    Original Article – Clinical Oncology 05 July 2022 Pages: 1883 - 1893

    

19. Immuno-histochemical correlation of fibrosis-related markers with the desmoplastic reaction of the mesentery in small intestine neuroendocrine neoplasms

    • Florian Bösch
    • Annelore Altendorf-Hofmann
    • Thomas Knösel

    Original Article – Clinical Oncology Open access 07 July 2022 Pages: 1895 - 1903

    

20. Lessons learned: the first consecutive 1000 patients of the CCCMunich^LMU Molecular Tumor Board

    • Kathrin Heinrich
    • Lisa Miller-Phillips
    • C. Benedikt Westphalen

    Original Article – Clinical Oncology Open access 07 July 2022 Pages: 1905 - 1915

    

21. Triple therapy in biliary tract cancers: GemOX plus immune checkpoint inhibitor in combination with lenvatinib or NGS-guided targeted therapy

    • Xiang Dong
    • Zewu Zhang
    • Wei Zhang

    Original Article – Clinical Oncology 08 July 2022 Pages: 1917 - 1927

    

22. Real-world treatment of German patients with recurrent and advanced endometrial cancer with a post-platinum treatment: a retrospective claims data analysis

    • Antje Mevius
    • Florian Karl
    • Thomas Wilke

    Original Article – Clinical Oncology Open access 16 July 2022 Pages: 1929 - 1939

    

23. Powering single-cell genomics to unravel circulating tumour cell subpopulations in non-small cell lung cancer patients

    • Emmanuel Acheampong
    • Michael Morici
    • Aaron B. Beasley

    Original Article – Clinical Oncology Open access 28 July 2022 Pages: 1941 - 1950

    

24. Long-term oncologic outcomes of robot-assisted versus open radical prostatectomy for prostate cancer with seminal vesicle invasion: a multi-institutional study with a minimum 5-year follow-up

    • Jungyo Suh
    • In Gab Jeong
    • Hanjong Ahn

    Original Article – Clinical Oncology 09 August 2022 Pages: 1951 - 1960

    

25. Osteosarcoma pre-diagnosed as another tumor: a report from the Cooperative Osteosarcoma Study Group (COSS)

    • Stefanie Hecker-Nolting
    • Daniel Baumhoer
    • Stefan S. Bielack

    Original Article – Clinical Oncology 18 August 2022 Pages: 1961 - 1967

    

26. Construction and validation of N6-methyladenosine long non-coding RNAs signature of prognostic value for early biochemical recurrence of prostate cancer

    • Jingchao Liu
    • Wei Zhang
    • Jianye Wang

    OriginalPaper 22 June 2022 Pages: 1969 - 1983

    

27. Attitude towards and perception of individual safety after SARS-CoV-2 vaccination among German cancer patients

    • Oliver Overheu
    • Simon Lendowski
    • Anke Reinacher-Schick

    OriginalPaper Open access 22 June 2022 Pages: 1985 - 1992

    

28. Hepatitis B virus reactivation in patients undergoing immune checkpoint inhibition: systematic review with meta-analysis

    • Zi-Niu Ding
    • Guang-Xiao Meng
    • Tao Li

    ReviewPaper 29 June 2022 Pages: 1993 - 2008

    

29. The protective effect of aspirin-induced temporary threshold shift in an animal model of cisplatin-related ototoxicity

    • Sharon Tzelnick
    • Aviram Mizrachi
    • Ohad Hilly

    OriginalPaper 01 July 2022 Pages: 2009 - 2016

    

30. The emerging role of anti-PD-1 antibody-based regimens in the treatment of extranodal NK/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis

    • Yanxia He
    • Yan Gao
    • Huiqiang Huang

    OriginalPaper 09 July 2022 Pages: 2017 - 2027

    

31. Clinical characteristics and prognostic factors of patients with non-small cell lung cancer having HER2 alterations

    • Xiaoli Zhuo
    • Honglin Guo
    • Guobin Fu

    OriginalPaper 13 July 2022 Pages: 2029 - 2039

    

32. LPAR2-mediated action promotes human renal cell carcinoma via MAPK/NF-κB signaling to regulate cytokine network

    • Yuewu Wang
    • Zhimin Qi
    • Alatangaole Damirin

    OriginalPaper 20 July 2022 Pages: 2041 - 2055

    

33. Phytotherapy known and applied by head-neck cancer patients and medical students to treat oral discomfort in Germany: an observational study

    • Maria-Louisa Ritschel
    • Jutta Hübner
    • Judith Büntzel

    OriginalPaper Open access 23 July 2022 Pages: 2057 - 2070

    

34. Immunotherapy for the treatment of advanced nasopharyngeal carcinoma: a promising new era

    • Shaoli Wang
    • Siying Chen
    • Yan Liu

    ReviewPaper 25 July 2022 Pages: 2071 - 2079

    

35. Prognostic utility of SOX2, STAT3, and CD44^high/CD24^low expression in penile cancer

    • Felipe Dubourcq de Barros
    • Leuridan Cavalcante Torres
    • Gustavo Cardoso Guimarães

    OriginalPaper 01 August 2022 Pages: 2081 - 2094

    

36. Looking at NSAIDs from a historical perspective and their current status in drug repurposing for cancer treatment and prevention

    • Adem Ozleyen
    • Yakup Berkay Yilmaz
    • Tugba Boyunegmez Tumer

    Review 25 July 2022 Pages: 2095 - 2113

    

37. Metabolic targeting of malignant tumors: a need for systemic approach

    • Aggelos T. Margetis

    Review 04 August 2022 Pages: 2115 - 2138

    

38. The efficacy of selinexor (KPT-330), an XPO1 inhibitor, on non-hematologic cancers: a comprehensive review

    • Jennifer R. Landes
    • Stephen A. Moore
    • Stephen K. Tyring

    Review 08 August 2022 Pages: 2139 - 2155

    

39. The benefits of vitamin A as a complementary treatment for oncology patients: a systematic review

    • Theresa Retzlaff
    • Jennifer Dörfler
    • Jutta Hübner

    Review 16 August 2022 Pages: 2157 - 2177

    

40. PD-1/PD-L1 inhibitors in treatment-naïve, advanced non-small cell lung cancer patients with < 1% PD-L1 expression: a meta-analysis of randomized controlled trials

    • Durgesh Wankhede
    • Paul Hofman
    • Sandeep Grover

    Review 19 August 2022 Pages: 2179 - 2189

    

41. Neutrophil extracellular traps facilitate cancer metastasis: cellular mechanisms and therapeutic strategies

    • Wenxing Hu
    • Serene M. L. Lee
    • Hanno Nieß

    Review Open access 01 September 2022 Pages: 2191 - 2210

    

42. The emerging roles and potential applications of circular RNAs in ovarian cancer: a comprehensive review

    • Sajad Najafi

    Review 02 September 2022 Pages: 2211 - 2234

    

43. Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival

    • Abdul Miah
    • Gabriel Tinoco
    • Dwight H. Owen

    Review 07 September 2022 Pages: 2235 - 2242

    

44. Novel targets for immunotherapy associated with exhausted CD8 + T cells in cancer

    • Lulu Zhang
    • Bo Zhang
    • Siji Nian

    Review 15 September 2022 Pages: 2243 - 2258

    

45. Metabolic changes during prostate cancer development and progression

    • Alicia-Marie K. Beier
    • Martin Puhr
    • Holger H. H. Erb

    Review Open access 23 September 2022 Pages: 2259 - 2270